Surmodics FY2027 EPS Estimate Decreased by Zacks Research

Surmodics, Inc. (NASDAQ:SRDX) – Zacks Research cut their FY2027 earnings per share (EPS) estimates for Surmodics in a research note issued to investors on Thursday, March 20th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.83 per share for the year, down from their previous estimate of $0.84. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share.

Several other research analysts have also issued reports on the company. Lake Street Capital upgraded Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Finally, StockNews.com assumed coverage on shares of Surmodics in a research note on Monday, February 3rd. They issued a “hold” rating on the stock. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $50.00.

Surmodics Price Performance

SRDX stock opened at $30.91 on Monday. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The stock has a market capitalization of $441.89 million, a PE ratio of -30.60 and a beta of 1.19. The company’s 50-day moving average is $33.24 and its 200-day moving average is $36.91. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29.

Surmodics (NASDAQ:SRDX) last released its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

Hedge Funds Weigh In On Surmodics

Large investors have recently bought and sold shares of the stock. Modus Advisors LLC bought a new stake in shares of Surmodics in the 4th quarter worth $40,000. Quest Partners LLC boosted its holdings in Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after purchasing an additional 1,071 shares during the last quarter. R Squared Ltd bought a new stake in Surmodics in the 4th quarter worth about $55,000. Longfellow Investment Management Co. LLC purchased a new stake in Surmodics in the 3rd quarter valued at about $67,000. Finally, Legal & General Group Plc lifted its position in shares of Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after buying an additional 880 shares in the last quarter. 96.63% of the stock is currently owned by institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).